Iloperidone Hypersensitivity Monitoring and Skin Testing

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Iloperidone treatment for schizophrenia is associated with adverse hypersensitivity reactions such as anaphylaxis, angioedema, and skin rashes, which are not adequately addressed in existing prescribing information, posing a risk for patients with known hypersensitivity.

Innovation Solution

Monitoring patients for hypersensitivity reactions like anaphylaxis, angioedema, and skin issues, and adjusting or discontinuing iloperidone treatment, with updated contraindications and adverse event reporting in the prescribing information to inform healthcare providers and patients about potential side effects.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If iloperidone is administered to treat schizophrenia, then antipsychotic efficacy is achieved, but hypersensitivity reactions such as anaphylaxis, angioedema, and skin rashes occur

Engineering Contradiction:

Improveantipsychotic efficacyVSAvoidhypersensitivity reactions

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent implements pre-treatment skin testing with iloperidone to identify patients at risk of hypersensitivity reactions before initiating full treatment. This preliminary action prevents severe adverse events by screening patients who would otherwise be exposed to the drug's harmful effects

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent establishes monitoring protocols during treatment to detect early signs of hypersensitivity reactions. By continuously monitoring patients and providing feedback on their response, the system can及时调整 treatment to prevent severe outcomes while maintaining therapeutic efficacy

Inventive Principle:

Principle #23Feedback

2Reliability

If prescribing information is updated to include hypersensitivity reactions, then patient safety is enhanced, but information complexity increases

Engineering Contradiction:

Improvepatient safetyVSAvoidinformation complexity

Core Design Contradiction:

ReliabilityVSLoss of information

Solution Approach 1:

The patent segments the prescribing information into distinct sections: contraindications for patients with known hypersensitivity, required pre-treatment skin testing protocols, monitoring requirements during treatment, and specific adverse reaction warnings. This segmentation organizes complex safety information into manageable, actionable components for healthcare providers

Inventive Principle:

Principle #1Segmentation

Data Source

PatentUS11723903B2Treatment of schizophrenia

Publication Date: 2023.08.15 VANDA PHARMACEUTICALS INC

AI summary

Aspects of the invention relate generally to the treatment of schizophrenia and to monitoring for specific adverse reactions.